Regeneus osteoarthritis treatment shows continued improvement
THE PHARMACY: Regenerative medicine company, Regeneus (ASX: RGS) announced further results from its ethics approved joint registry used to track the safety and effectiveness of the company’s innovative cell therapy, HiQCell®, in the treatment of osteoarthritis.
The interim report of 305 patients, as at 23 January 2014, has found that:
Patients reported continued improvements at 12 months post-treatment;
The small number of patients (7) within the Registry that had reached 24 months post-treatment also show continued improvements;
Patients reported improvements in pain, function, sleep quality and reduced usage of pain medications;
73 per cent of patients treated experienced a (greater than 30 per cent) reduction in pain with an average reduction of 79 per cent across all age groups and osteoarthritis grades; and
HiQCell is a safe therapy and well tolerated by patients.
Percentage of pain level for responders experiencing more than 30
per cent pain reduction from baseline. Source: Company announcement
Regeneus explained the HiQCell Joint Registry as being the first of its kind in the long-term follow-up of patients undergoing stem cell therapy using the patient’s own fat-derived stem cells.
Patients in the Registry will continue to be followed for up to five years with analyses updated regularly.
Within the registry a patient is classified as a responder if they report a greater than 30 per cent reduction in pain.
At 12 months post treatment 56 of 77 patients were responders and at 24 months post treatment
6 of 7 patients were responders.
“The Joint Registry is an important part of the company’s commitment to quality,” Regeneus CEO, professor Graham Vesey said in the company’s announcement to the Australian Securities Exchange.
“Recording patient outcomes over the long term is an example of our responsible approach towards furthering the medical community’s understanding of this new therapeutic field.
“It is exciting that we have registry data available for 12 months and beyond post-treatment for patients.
“We anticipate that it will also help us to build a case for permitting medical reimbursement to patients.”
The Joint Registry is a voluntary observational registry and all patients treated with HiQCell are eligible for inclusion.
Patients are tracked from a pre-treatment baseline, at two weeks, at six months and then annually.
Three hundred and five patients had consented to be included in the registry as of 23 January 2014, representing 77 per cent of all patients treated.
Email: investors@regeneus.com.au
Website: www.regeneus.com.au